3430-19-1Relevant articles and documents
Synthesis method of 3-bromo-5-methylpyridine
-
Paragraph 0025, (2017/10/07)
The invention relates to the field of organic chemistry and particularly provides a synthesis method of 3-bromo-5-methylpyridine. The synthesis method includes the steps of: 1) performing a reaction to diethyl malonate and alkaline metal to generate a salt, and dropwise adding a toluene solution of 3-nitro-5-chloropyridine to perform a condensation reaction, and decarboxylating the product under an acidic condition to obtain 3-nitro-5-methylpyridine; 2) performing hydrogenation reduction to the 3-nitro-5-methylpyridine with Pd/C as a catalyst and methanol as a solvent, performing suction filtration and concentrating a filtrate to prepare 3-amino-5-methylpyridine; and 3) performing a reaction to the 3-amino-5-methylpyridine with an acid to generate a salt, and cooling the salt to -10 - 0 DEG C, dropwise adding liquid bromine, and then dropwise adding a sodium nitrite water solution, regulating the pH value of the solution to alkalinity and performing extraction, drying and concentration to obtain the 3-bromo-5-methylpyridine. The synthesis method is mild in reaction conditions, is high in yield, employs easy-to-obtained raw materials, is low in cost, is short in process route and has industrial prospect.
COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS
-
Page/Page column 75, (2012/11/06)
The invention relates to compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating diseases and disorders.
Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder
Perez-Medrano, Arturo,Brune, Michael E.,Buckner, Steven A.,Coghlan, Michael J.,Fey, Thomas A.,Gopalakrishnan, Murali,Gregg, Robert J.,Kort, Michael E.,Scott, Victoria E.,Sullivan, James P.,Whiteaker, Kristi L.,Carroll, William A.
, p. 6265 - 6273 (2008/04/05)
A series of novel cyanoguanidine derivatives was designed and synthesized. Condensation of N-(1-benzotriazol-1-yl-2,2-dichloropropyl)-substituted benzamides with N-(substituted-pyridin-3-yl)-N′-cyanoguanidines furnished N-{2,2-dichloro-1-[N′-(substituted-pyridin-3-yl)-N′-cyanoguanidino] propyl}-substituted benzamide derivatives. These agents were glyburide-reversible potassium channel openers and hyperpolarized human bladder cells as assessed by the FLIPR membrane potential dye (KATP-FMP). These compounds were also potent full agonists in relaxing electrically stimulated pig bladder strips, an in vitro model of overactive bladder. The most active compound 9 was evaluated for in vivo efficacy and selectivity in a pig model of bladder instability. Preliminary pharmacokinetic studies in dog demonstrated excellent oral bioavailability and a t1/2 of 15 h. The synthesis, SAR studies, and biological properties of these agents are discussed.